Abstract 49P
Background
There is scant data on outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy in real-world, resource-constrained settings. Factors affecting outcomes in patients who achieve pathological complete response (pCR) are insufficiently explored.
Methods
This was a retrospective analysis of HER2-positive breast cancer patients treated with neoadjuvant chemotherapy (NACT) with or without HER2-targeted therapy between Jan 2014 & Dec 2018. The endpoints were pCR, event-free survival (EFS) and overall survival (OS).
Results
1004 patients were included in the analysis with a median age of 47 years, 533 (53.1%) with cT3/T4, 466 (46.4%) with cN2/3, 527 (52.5%) with ER/PR-positive tumours, 528 (52.3%) received HER2-therapy with NACT, and 711 (70.8%) received it anytime during curative treatment. The 5-year EFS in all patients was 63.5% (95%CI 60.36-66.63%) and was significantly higher with pCR vs without pCR (86.1% vs 57.0%, HR 0.282, 95%CI 0.198-0.401, p=0.000), cT1/T2 vs cT3/T4 (66.8% vs 60.6%, HR 0.767, 95%CI 0.626-0.939, p=0.01), cN0/N1 vs cN2/N3 (67.9% vs 58.5%, HR 0.772, 95%CI 0.632-0.944, p=0.01), and ever-received vs never-received HER2-therapy (69.5% vs 50.1%, HR 0.537, 95%CI 0.438-0.659, p=0.000). The 5-year OS in all patients was 69.6% (95%CI 66.66-72.54%) and was significantly higher in pCR, cT1/T2, cN0/N1, and ever-received HER2-therapy subgroups. In the pCR subgroup (n=226), there was a trend towards higher 5-year EFS among patients with cT1/T2 vs cT3/T4 (90.0% vs 82.5%, HR 0.546, 95%CI 0.270-1.103, p=0.08), cN0/N1 vs cN2/N3 (89.3% vs 82.4%, HR 0.641, 95%CI 0.326-1.262, p=0.195), and ER/PR-positive) vs ER/PR-negative tumours (90.9% vs 83.0%, HR 0.609, 95%CI 0.291-1.274, p=0.183), but there was no difference between ever-received (n=204) vs never-received (n=22) HER2-therapy (86.1% vs 86.4%, HR 0.880, 95%CI 0.309-2.504, p=0.811).
Conclusions
The receipt of HER2-targeted therapy and achievement of pCR significantly impact survival of HER2-positive breast cancer patients treated with neoadjuvant therapy. In patients who achieve pCR baseline disease burden tends to influence survival but not receipt of HER2-targeted therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract